Beckman Coulter expands flow cytometry portfolio
This article was originally published in Clinica
Executive Summary
Beckman Coulter Life Sciences has acquired the flow cytometry business of ReaMetrix India, a Bangalore-based life science technology company. ReaMetrix was among the first to bring to the market dry, room temperature-stable reagents for in vitro diagnostic use, according to Beckman Coulter. The products, which are CE-marked but not yet cleared by the US FDA, are used for routine clinical analyses, specifically HIV monitoring and clinical research, two key flow cytometry market segments. They help to “simplify the sample preparation process” and in turn increase productivity of cytometrists, and will enable to broaden Beckman’s existing flow cytometry offerings.